Orally active bistriazole antifungal agent. Prepn: K. Richardson, GB 2099818; idem, US 4404216 (1982, 1983 both to Pfizer). Antifungal activity in vivo: K. Richardson et al., Antimicrob. Agents Chemother. 27, 832 (1985); and in vitro: T. E. Rogers, J. N. Galgiani, ibid. 30, 418 (1986). Pharmacokinetics: M. J. Humphrey et al., ibid. 28, 648 (1985). GC determn in human plasma and urine: P. R. Wood, M. H. Tarbit, J. Chromatogr. 383, 179 (1986). Evaluation as maintenance therapy for cryptococcal meningitis in AIDS patients: S. A. Bozzette et al., N. Engl. J. Med. 324, 580 (1991). Symposium on mode of action, toxicology, animal models and clinical studies: International Telesymposium on Recent Trends in the Discovery, Development and Evaluation of Antifungal Agents Section 2, R. A. Fromtling, Ed. (J. R. Prous Science Publ., Barcelona, 1987) pp 77-174. Infection prophylaxis in bone marrow transplantation patients: M. L. MacMillan et al., Am. J. Med. 112, 369 (2002). Review of use in treatment of invasive candidiasis: C. Charlier et al., J. Antimicrob. Chemother. 57, 384-410 (2006).
Prepn: C. W. Murtiashaw et al., WO 9728169; S. Green et al., US 6790957 (1997, 2004 both to Pfizer). Review of discovery and commercial process development: A. Bentley et al., Org. Process Res. Dev. 6, 109-112 (2002).
Antifungal.
Antifungal (Synthetic); Triazoles